Generation Bio Co. Common Stock
GBIO US37148K1007
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Quinn Anthony G. O |
0.97 USD |
85,000 Bought |
82,450 USD |
10/01/2025 | 13/01/2025 |
Quinn Anthony G. O |
0.96 USD |
125,791 Bought |
120,759 USD |
10/01/2025 | 10/01/2025 |
Paone Antoinette COO |
2.74 USD |
6,719 Sold |
18,410 USD |
01/07/2024 | 01/07/2024 |
Paone Antoinette COO |
1.62 USD |
2,445 Sold |
3,961 USD |
02/01/2024 | 02/01/2024 |
Samayoa Phillip SR OFF |
1.62 USD |
2,445 Sold |
3,961 USD |
02/01/2024 | 02/01/2024 |
Appelhans Dannielle O |
1.82 USD |
637 Bought |
1,159 USD |
08/12/2023 | 08/12/2023 |
Appelhans Dannielle O |
1.79 USD |
7,363 Bought |
13,180 USD |
08/12/2023 | 08/12/2023 |
Appelhans Dannielle O |
1.50 USD |
12,000 Bought |
18,000 USD |
04/12/2023 | 04/12/2023 |
Rowland Charles A Jr O |
1.50 USD |
150,000 Bought |
225,000 USD |
01/12/2023 | 04/12/2023 |
Quinn Anthony G. O |
1.41 USD |
88,495 Bought |
124,778 USD |
01/12/2023 | 01/12/2023 |